FORCE advocates for families facing hereditary cancer in areas such as access to care, research funding, insurance and privacy.

Policy Archive

FORCE Weighs in on Breast Implant Safety and Informed Consent

Device Safety & Drug Development

December 23, 2019 - Today, FORCE submitted comments on U.S. Food and Drug Administration's proposed labeling and patient communication guidelines for breast implants. These updates follow a device safety hearing and recall of certain textured breast implants earlier this year. If enacted, the guidance will revise those established in 2006 by adding a boxed warning, patient decision checklist, revised rupture screening recommendations, and more.

The proposed changes follow July 2019 action to protect women from breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) by requesting that Allergan, the manufacturer of a specific type of textured implant, recall certain models of its textured breast implants from the U.S. market due to the risk of BIA-ALCL.

Per the agency's request, Allergan recalled its BIOCELL textured breast implant products, including: Natrelle Saline-Filled breast implants, Natrelle Silicone-Filled breast implants, Natrelle Inspira Silicone-Filled breast implants, and Natrelle 410 Highly Cohesive Anatomically Shaped Silicone-Filled breast implants. The recall also includes tissue expanders used by patients prior to breast augmentation or reconstruction, including Natrelle 133 Plus Tissue Expander and Natrelle 133 Tissue Expander with Suture Tabs.

Read our XRAY review for a more in-depth analysis of the recall and related issues.

See the "Related Resources" box below for more history behind this new guidance, recall, and FDA meetings that took place earlier this year.

Take Action Now 2021 Priorities Advocacy Archive Public Policy Initiatives

News Briefs

7/1/2021 - Effective today, North Carolina's Medicaid program will cover genetic counseling and BRCA mutation testing for those who have "higher than average risk" for the development of certain cancers based on specific personal and/or family history of the disease.

6/30/2021 - FORCE added its support to a letter sent to Senate HELP Committee leadership urging the prioritization of diagnostics reform on behalf of the In-vitro Diagnostics (IVD) Reform Coalition and the communities it represents.

5/21/2021 - Joined the Defense Health Research Consortium in a letter asking House and Senate leadership to continue support for the defense health research programs funded through the Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP). 

More